Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations-Reference-Cited by-同舟云学术

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

Published:2011-12 Issue:6 Volume:54 Page:1924-1935
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Fridell Robert A.,Wang Chunfu,Sun Jin-Hua,O'Boyle Donald R.,Nower Peter,Valera Lourdes,Qiu Dike,Roberts Susan,Huang Xin,Kienzle Bernadette,Bifano Marc,Nettles Richard E.,Gao Min

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.24594/fullpdf

Reference13 articles.

1. Hepatitis C virus NS5A: tales of a promiscuous protein;Macdonald;J Gen Virol,2004

2. Cellular cofactors affecting hepatitis C virus infection and replication;Randall;Proc Natl Acad Sci U S A,2007

3. Identification of residues required for RNA replication in domain II and III of the hepatitis C virus NS5A protein;Tellinghuisen;J Virol,2008

4. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical efficacy;Gao;Nature,2010

5. Resistance analysis of the HCV NS5A inhibitor, BMS-790052, in the in vitro replicon system;Fridell;Antimicrob Agents Chemother,2010

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antivirales de acción directa contra la hepatitis C: revisión narrativa;Hepatología;2024-05-02

2. Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus;Viruses;2023-04-17

3. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

4. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection;JGH Open;2022-05

5. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients;Microbial Pathogenesis;2022-01